by barry101 | Jun 12, 2024 | Press Releases
Live video webcast on Tuesday, June 18th at 3:00 PM ET HOUSTON, June 12, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
by barry101 | Jun 5, 2024 | Press Releases
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET HOUSTON, June 5, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...
by barry101 | May 16, 2024 | Press Releases
HOUSTON, May 16, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced...
by barry101 | May 15, 2024 | Press Releases
– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune “memory” in...
by barry101 | May 13, 2024 | Press Releases
– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) – Also announced MB-106 reaches 20 subjects enrolled...
by barry101 | May 9, 2024 | Press Releases
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 — Moleculin...
